Novo Nordisk A/S: Novo Nordisk receives positive opinion on Xultophy(r) (IDegLira) from the European regulatory authorities

Bagsvaerd, Denmark, July 25, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults.

Xultophy® is the intended brand name for IDegLira, the first once-daily single injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide), developed for the treatment of type 2 diabetes. The CHMP positive opinion recommends that Xultophy® will be indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.

For further information

Lars Pallisgaard +45 3079 3730 lplg@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company announcement No 45 / 2014

Company Announcement No 45 2014 http://hugin.info/2013/R/1837250/638603.pdf


Source:Novo Nordisk A/S